Lobbying

Therapeuticsmd TXMD's latest lobbying report covers Q4 2022, at $40K. Its first report covers Q4 2022; the issues it reports most are Health Issues.

TherapeuticsmdTXMD

Therapeuticsmd stock page

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Therapeuticsmd lobbying by quarter
Therapeuticsmd lobbying by quarter
QuarterAmountReports
Q4 2022$40K1
Q1 2023$00
Q2 2023$00
Q3 2023$00
Q4 2023$00
Q1 2024$00
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$40K · 1 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Health & Human Services, Dept of (HHS)1 reports
  • HOUSE OF REPRESENTATIVES1 reports
  • SENATE1 reports

Firms it paid

Firm
Sims Strategies$40K1 quarters

Former officials lobbying for it

Former position
EDWARD PRETTYMANLegislative Correspondent and Constituent Services Representative, Sen. Tom Carper (D-DE)Q4 2022
MICHAELA SIMSLegislative Counsel, Sen. Ben Nelson (D-NE); Legislative Director and Counsel, Sen. Bob Kerrey (D-NE)Q4 2022

Lobbying reports

Filed by
23/01/19for Q4 2022Sims Strategies$40K